drugset / Trial / NCT00667069

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

NCT00667069 ↗

Phase 3 Completed 424 enrolled UNICANCER Ipsen · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether giving triptorelin and radiation therapy soon after surgery or later after surgery is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying giving triptorelin and radiation therapy soon after surgery to see how well it works compared with giving them later after surgery in treating patients who have undergone surgery for intermediate-risk stage III or stage IV prostate cancer.

Timeline

Start
2008-04-07
Primary completion
2020-04
Completion
2022-05-24

Outcome

Missed primary endpoint

paper we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. PMID 33002438 ↗

paper (HR 0·81, 95% CI 0·48-1·36; log-rank p=0·42). PMID 33002438 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptorelin Other / unclassified — Intramuscular

Indications